Parsons Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Parsons Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,816	Closed	-$76K	–	416
2020 Q4	$76K	Hold	10,816	–	–	0.01%	372
2020 Q3	$88K	Hold	10,816	–	–	0.01%	346
2020 Q2	$75K	Hold	10,816	–	–	0.01%	330
2020 Q1	$51K	Hold	10,816	–	–	0.01%	310
2019 Q4	$94K	Hold	10,816	–	–	0.01%	341
2019 Q3	$36K	Hold	10,816	–	–	﹤0.01%	338
2019 Q2	$54K	Hold	10,816	–	–	0.01%	345
2019 Q1	$67K	Hold	10,816	–	–	0.01%	339
2018 Q4	$36K	Hold	10,816	–	–	﹤0.01%	326
2018 Q3	$70K	Hold	10,816	–	–	0.01%	350
2018 Q2	$83K	Sell	10,816 -200	-2%	-$2.88K	0.01%	350
2018 Q1	$246K	Sell	11,016 -32,000	-74%	-$710K	0.03%	326
2017 Q4	$548K	Hold	43,016	–	–	0.06%	250
2017 Q3	$670K	Buy	+43,016	New	+$608K	0.08%	215

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parsons Capital Management's JNCE Position: Q1 2021 in Review

Parsons Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 10,816 shares — an estimated $76K sold.

Parsons Capital Management first reported a position in JNCE in Q3 2017 and held it in 14 quarters. The position peaked at $670K in Q3 2017. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

Parsons Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Parsons Capital Management sold 10,816 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $76K.
Parsons Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 14 quarters.
Parsons Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $670K in Q3 2017.
124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Parsons Capital Management's 13F filing for Q1 2021, filed 28 Apr 2021.